Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 11, 2024Clinical Cancer Research

Metabolic tumor volume response after bridging therapy determines chimeric antigen receptor T-cell outcomes in large B cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HHHarper HubbelingUniversity of PennsylvaniaDLDoris LeithnerNYU Langone HealthESEmily A. SilvermanUniversity of Nebraska at Omaha

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hubbeling et al. (2024) studied this question.

synapsesocial.com/papers/68e58cbfb6db643587528471https://doi.org/10.1158/1078-0432.ccr-24-0830
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma2020 · 255 citations
  2. 2ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells2018 · 3,694 citations
  3. 3Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma2021 · 136 citations
  4. 4Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use2023 · 35 citations